Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: A phase IIa randomized clinical trial

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Munseri, Patricia J ^a,b   Kroidl, Arne ^c,d,e   Nilsson, Charlotta ^b,f   Joachim, Agricola ^a   Geldmacher, Christof ^d,e   Mann, Philipp ^c,d   Moshiro, Candida ^a   Aboud, Said ^a   Lyamuya, Eligius ^a   Maboko, Leonard ^c   Missanga, Marco ^c   Kaluwa, Bahati ^c   Mfinanga, Sayoki ^c   Podola, Lilly ^c,d   Bauer, Asli ^c,d   Godoy Ramirez, Karina ^f   Marovich, Mary ^g,h   Moss, Bernard ⁱ   Hoelscher, Michael ^c,d,e   Gotch, Frances ^j   Stöhr, Wolfgang ^k   Stout, Richard ^l   McCormack, Sheena ^k   Wahren, Britta ^b   Mhalu, Fred ^a   Robb, Merlin L ^g,h   Biberfeld, Gunnel ^b,f   Sandström, Eric ^b   Bakari, Muhammad ^a   more..

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e German Center for Infection Research   (Germany)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l Bioject Medical Technologies   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MODIFIED VACCINIA ANKARA CHIANG MAI DOUBLE RECOMBINANT VACCINE; PLACEBO; UNCLASSIFIED DRUG; MVA VACCINE; VIRUS DNA; VIRUS VACCINE;

ADULT; ALLERGIC CONJUNCTIVITIS; ANEMIA; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; FAINTNESS; FEMALE; GASTROENTERITIS; HEADACHE; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; KNEE DISLOCATION; MALARIA; MALE; MENSTRUATION DISORDER; NEUTROPENIA; NORMAL HUMAN; PAIN; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKULL FRACTURE; TANZANIAN; TONSILLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; T LYMPHOCYTE; TANZANIA; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; DNA, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; MALE; T-LYMPHOCYTES; TANZANIA; VACCINES, DNA; VIRAL VACCINES;

EID: 84928777887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119629     Document Type: Article

References (33)

1. UNAIDS (2013) UNAIDS report on the global AIDS epidemic 2013.
2. UNAIDS (2014) Fast-TracK: Ending the AIDS Epidemic by 2030.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174. doi: 10.1126/science.1193748 PMID: 20643915
4. Cicconi P, Monforte A, Castagna A, Quirino T, Alessandrini A, et al. (2013) Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study. J Int AIDS Soc 16: 18591. doi: 10.7448/IAS.16.1.18591 PMID: 24135086
5. Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, et al. (2013) Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr 63 Suppl 1: S12-25. doi: 10.1097/QAI.0b013e31829202a2 PMID: 23673881
6. Fauci AS, Marston HD (2014) Ending AIDS - is an HIV vaccine necessary? N Engl J Med 370: 495-498. doi: 10.1056/NEJMp1313771 PMID: 24499210
7. Fauci AS, Folkers GK, Marston HD (2014) Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis 59 Suppl 2: S80-84. doi: 10.1093/cid/ciu420 PMID: 25151483
8. Saunders KO, Rudicell RS, Nabel GJ (2012) The design and evaluation of HIV-1 vaccines. AIDS 26: 1293-1302. doi: 10.1097/QAD.0b013e32835474d2 PMID: 22706011
9. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, et al. (2011) Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204: 164-173. doi: 10.1093/infdis/jir199 PMID: 21628671
10. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, et al. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 3: 81ra36. doi: 10.1126/scitranslmed.3002351 PMID: 21543722
11. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93. doi: 10.1038/nature10766 PMID: 22217938
12. Freel SA, Saunders KO, Tomaras GD (2011) CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunol Res 49: 135-146. doi: 10.1007/s12026-010-8177-7 PMID: 21170741
13. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, et al. (2012) HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 4: 123ra125.
14. O'Connell RJ, Kim JH, Corey L, Michael NL (2012) Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2: a007351. doi: 10.1101/cshperspect.a007351 PMID: 23209178
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi: 10.1056/NEJMoa0908492 PMID: 19843557
16. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL (2010) HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 5: 428-434. doi: 10.1097/COH.0b013e32833d17ac PMID: 20978385
17. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. doi: 10.1056/NEJMoa1113425 PMID: 22475592
18. Excler JL, Tomaras GD, Russell ND (2013) Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 8: 421-431. doi: 10.1097/COH.0b013e3283632c26 PMID: 23743791
19. Walker BD, Ahmed R, Plotkin S (2011) Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 17: 1194-1195. doi: 10.1038/nm.2529 PMID: 21988996
20. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, et al. (2011) Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29: 8417-8428. doi: 10.1016/j.vaccine.2011.08.001 PMID: 21864626
21. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490. doi: 10.1086/592507 PMID: 18808335
22. Nilsson C, Godoy-Ramirez K, Hejdeman B, Brave A, Gudmundsdotter L, et al. (2014) Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses 30: 299-311. doi: 10.1089/AID.2013.0149 PMID: 24090081
23. Brave A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, et al. (2005) Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 12: 1197-1205. PMID: 16112909
24. Brave A, Ljungberg K, Boberg A, Rollman E, Engstrom G, et al. (2006) Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 24: 4524-4526. PMID: 16174543
25. Earl PL, Cotter C, Moss B, VanCott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895. doi: 10.1016/j.vaccine.2009.07.039 PMID: 19654066
26. DAIDS (2004) Division of AIDS Table for Grading The Severity of Adult and Pediatric Adverse Events. 1.0 ed.
27. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172. PMID: 11792386
28. Haddy TB, Rana SR, Castro O (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133: 15-22. PMID: 10385477
29. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WB, et al. (2008) Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One 3: e3327. doi: 10.1371/journal.pone.0003327 PMID: 18833329
30. Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, et al. (2008) Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS One 3: e3919. doi: 10.1371/journal.pone.0003919 PMID: 19079547
31. Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, et al. (2012) Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One 7: e45840. doi: 10.1371/journal.pone.0045840 PMID: 23049876
32. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, et al. (2011) Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 203: 610-619. doi: 10.1093/infdis/jiq105 PMID: 21282192
33. Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, et al. (2013) Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS One 8: e55831. doi: 10.1371/journal.pone.0055831 PMID: 23418465